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Traditionally, catheter-based intervention to treat chroni-
cally occluded coronary arteries has been associated with
poorer acute and long-term success compared with inter-
vention on patent arteries (1,2). From the earliest days of
balloon angioplasty, the main challenge in revascularization
of a coronary occlusion has been the ability to pass a
guidewire through the area of occlusion into the “true
lumen” of the distal vessel. Despite quantum gains made in
the ability to treat other difficult lesion subsets, such as
aorto-ostial stenoses and saphenous vein graft disease, the
technology needed to safely and predictably revascularize
the chronically occluded coronary artery has been elusive.
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The development of stiffer and lubricious guidewires coated
with hydrophilic polymers has led to modest improvement
in the ability of the interventionalist to cross these occlu-
sions. Yet none of these wires has met with predictable
success. Beyond simple guidewire technology, there are
several innovative devices that extend the armamentarium of
the interventionalist in his/her quest to conquer this formi-
dable adversary. The Frontrunner CTO Catheter (Lumend
Inc., Redwood City, California) is a blunt dissection device
that creates controlled dissection planes in the plaque,
allowing the operator to then pass a conventional wire. The
Safe-Steer wire (IntraLuminal Therapeutics Inc., Carlsbad,
California) utilizes optical coherence reflectometry technol-
ogy to guide transit of the wire through plaque and away
from the arterial wall.
However, successful passage of the guidewire through the
occlusion is only the first hurdle that must be overcome to
achieve long-term arterial patency. Early generation bal-
loons had difficulty crossing these lesions and were intoler-
ant of high pressures often required to dilate these lesions.
Newer, low-profile balloons, which can be expanded with
high pressure, and atheroablative devices facilitate acute
luminal enlargement. Nevertheless, the high plaque burden
and diffuse disease commonly associated with chronic oc-
clusion predispose to a high incidence of restenosis (3).
Even when the occlusion is crossed and the lesion dilated,
the rates of restenosis may be as high as 70% with balloon
angioplasty alone (2). Given the unequivocal successes of
endovascular stenting for treating other lesions subsets
associated with high rates of restenosis, it was natural to
hypothesize that this breakthrough technology would yield
favorable effects when treating chronic coronary occlusions
(4–6).
Initially, many operators were reluctant to stent chronic
occlusions out of fear of subacute stent thrombosis resulting
from flow reduction due to retrograde collateral filling.
However, several randomized clinical trials have docu-
mented that stenting is associated with better acute angio-
graphic outcome and freedom from restenosis and need for
repeat revascularization of chronic coronary artery occlusion
(7–9). In one such study, the Gruppo Italiano di Studio
sullo Stent nelle Occlusioni Coronariche (GISSOC) trial
(8), postprocedure minimum lumen diameter was signifi-
cantly larger (2.46 vs. 1.91 mm) in patients randomized to
stent placement. By nine months, follow-up angiography
demonstrated a 53% reduction in angiographic restenosis in
stented lesions. Furthermore, the worst-case scenario of
restenosis (i.e., complete reocclusion) was also significantly
reduced by stenting (8% vs. 34%). More importantly, this
translated into a more favorable clinical outcome, with a
marked reduction in the need for repeat revascularization of
the target lesion from 22% to 5.3%. Although these findings
are impressive and certainly validate the concept of stenting
for treatment of chronic occlusions, it is merely one “snap-
shot” in the temporal continuum of a chronic disease.
Naively, many in the interventional community have
traditionally assumed that freedom from angiographic re-
stenosis at six to nine months guaranteed long-term patency
and freedom from clinical events. We now have a more
realistic appreciation that additional revascularization events
driven by target lesion restenosis occur beyond this time
interval (10). As newer treatment modalities that alter the
biologic response to arterial injury (e.g., vascular brachyther-
apy and drug-eluting stents) become incorporated into
everyday practice, it is imperative that we collect extended
follow-up data to ensure that the salutary outcomes reported
within the first year are maintained.
In this context, Rubartelli et al. (11), in this issue of the
Journal, are to be commended for extending the follow-up
of the GISSOC trial to six years. The major criticism of the
original GISSOC study relates to the characteristics of the
treated lesions. Approximately one-third of the lesions had
a Thrombolysis In Myocardial Infarction (TIMI) flow
grade 0, and small vessels (3.0 mm) and long lesions
(13 mm) were excluded. Furthermore, the relative dura-
tion of the occlusion was relatively brief. Thus, the findings
of the GISSOC study may not be generalizable to all
patients with chronic total occlusions. Nevertheless, clinical
follow-up at six years supports the superiority of stenting
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compared with balloon angioplasty alone. Percutaneous
coronary intervention with stenting afforded greater free-
dom from target lesion revascularization (14.9% vs. 34.5%,
p  0.0165) compared with angioplasty alone. Although
the incidence of other clinical end points, such as death or
nonfatal myocardial infarction, did not differ, the small
GISSOC study is clearly underpowered to detect a signifi-
cant difference in these outcomes. Also, approximately
two-thirds of the patients enrolled had single-vessel coro-
nary artery disease with a low incidence of diabetes mellitus
and reduced ejection fraction, portending an excellent long-
term prognosis for the entire cohort.
The favorable outcome reported for lesions treated with
stenting in the GISSOC study is even more impressive
when one considers that the stent deployed in these pa-
tients, the Palmaz-Schatz coronary stent (Cordis Corp.,
Miami Lakes, Florida), was a “first generation” device with
significant structural limitations, such as the presence of an
articulation site and rigid segments. In addition, the oper-
ators hand-crimped these stents and deployed them at
relatively low pressures. It is generally accepted that subop-
timal stenting techniques (low pressure deployment and
incomplete expansion) are associated with poorer acute and
long-term outcome. In the GISSOC study, the post-
treatment residual stenosis was 18%, suggesting that later
generation stents deployed using optimal stenting tech-
niques may have led to even better outcomes in the stent
cohort. The use of the archaic warfarin-based pharmaco-
logic regimen rather than the more contemporary dual
antiplatelet therapy probably explains the 4.7% incidence of
hemorrhagic complication observed in the patients treated
with stents.
Despite these impressive findings in the GISSOC study,
the decision to attempt catheter-based intervention on any
given patient with a chronic total occlusion must be made
on a lesion-by-lesion basis. If the patient is asymptomatic
and there is no evidence of provokable ischemia in the
myocardium subtended by the occluded vessel, it is difficult
to justify subjecting the patient to the risk, albeit low, of
attempted revascularization. If there is clinical evidence of
ischemia, consideration should be given to attempted per-
cutaneous revascularization. Although it is sometimes said
that restoring patency to a chronically occluded coronary
occlusion does not change long-term prognosis, Suero et al.
(12) recently reported that successful revascularization of a
chronically occluded coronary artery was independently as-
sociated with improved 10-year survival.
Nevertheless, interventional cardiologists must carefully
weigh factors predictive of success in crossing coronary total
occlusions, such as operator experience, larger vessel size,
younger age of occlusion, shorter lesion length, absence of
proximal vessel tortuosity, minimal bridging collaterals, and
presence of a tapering funnel at the end of the occlusion
(13). If the occluded segment of the artery can be traversed
with a conventional guidewire or one of the newer total
occlusion devices, documenting the presence of the wire in
the true lumen of the vessel is mandatory before balloon
dilation. Following balloon dilation, in light of the GIS-
SOC study results, stand-alone balloon angioplasty can no
longer be justified unless endoluminal stenting cannot be
performed safely. Every effort should be made to optimize
the acute angiographic outcome because every large pro-
spective analysis supports the link between greater post-
treatment lumen diameter and freedom from angiographic
and clinical restenosis (10). “Bigger is still better,” at least in
the bare stent era. Ultimately, drug-eluting stents may
provide additional benefit to the impressive results docu-
mented with bare stents in the GISSOC trial. Preliminary
data from the randomized Sirolimus-Eluting Stent in De
Novo Native Coronary Lesions (SIRIUS) trial showed a
75% reduction in angiographic restenosis and target lesion
revascularization in patients treated with the sirolimus-
eluting stents compared with bare stents. Although the use
of drug-eluting stents has not been prospectively evaluated
for the treatment of chronic total occlusion, there is hope
that the extraordinary results reported for nonoccluded
vessels may also be realized in this high-risk subset. The
combination of improved technology to safely cross the
occlusion and future generation stents may affirm that we
are indeed “one step closer” to the necessary “one-two
punch” needed to achieve long-term patency for endovas-
cular treatment of total coronary occlusion.
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